ALUR
BEARISH
$0.53
Live
Allurion Technologies Inc. · NYSE
Target $5.5
(+937.7%)
$0.23
52W Range
$3.5
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 25, 2026
Market cap
$7.92M
P/E
N/A
ROE
N/A
Profit margin
-187.9%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ALUR exhibits severe financial distress with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability, collapsing revenue growth, and negative ROA (-71.87%) signal high distress risk. Despite a gross margin of 60.99%, the company is losing money at an accelerating rate, with a -187.87% profit margin and -362.30% operating margin. The stock trades at a deeply discounted price of $0.53, but this reflects a market pricing in failure rather than value. Analysts have a target of $5.50, but with no consensus recommendation and a 5-year return of -99.8%, the outlook remains bleak.
Key Strengths
Gross margin of 60.99% indicates strong product-level pricing power or cost control
Recent quarterly earnings have shown positive surprises (avg +25.09%) in the last four quarters
Insider activity, though bearish, is minimal (only one sale in 6 months)
Price/Sales of 0.46 suggests the stock is trading at a discount to revenue
One of the few healthcare companies with a positive EPS growth trend (YoY +74.0%) despite losses
Key Risks
Piotroski F-Score of 0/9 indicates severe financial deterioration and operational failure
Revenue declined 50.5% YoY, signaling a collapsing business model
Negative ROA (-71.87%) and negative operating margin (-362.30%) reflect deep operational inefficiency
No available debt/equity or cash data raises transparency and solvency concerns
Insider selling (1 transaction) and bearish technical trend (0/100) signal lack of confidence
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
15
Weak
30
20
15
10
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 0/9, Negative revenue and earnings growth, Negative profitability metrics, Lack of financial transparency (missing cash, debt, equity), Extreme price decline (-99.8% over 5 years)
Confidence
90%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 0.46 is low relative to sector
- Trading below 52-week low ($0.23) and current price ($0.53)
Watchpoints
- No Graham Number or intrinsic value due to negative earnings and no stable growth
- Negative P/E and PEG ratios make valuation models inapplicable
- Market cap of $0.01B suggests extreme undervaluation, but likely due to failure risk
Future
20/100
Ref Growth rates
Positives
- Recent YoY EPS growth of +74.0% (though from deeply negative base)
- Positive earnings surprises in 3 of last 4 quarters
Watchpoints
- Revenue growth down 50.5% YoY
- Q/Q EPS growth of -35.6%
- No forward P/E or earnings guidance available
- No clear path to profitability despite margin strength
Past
15/100
Ref Historical trends
Positives
- Historical earnings have shown volatility with large positive surprises (e.g., +156.9%)
Watchpoints
- Consistent negative earnings across all 9 quarters
- Profit margin deteriorated from -187.87% to worse
- 52-week low of $0.23 and 5-year return of -99.8% reflect long-term decline
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.26 suggests short-term liquidity is intact
- Quick ratio of 0.87 is below ideal but not catastrophic
Watchpoints
- Piotroski F-Score of 0/9 indicates complete failure in financial health
- No available Altman Z-Score, but negative ROA and margins suggest distress
- Negative ROIC and ROE (N/A) imply capital is not being deployed effectively
- No available debt/equity or cash data raises red flags
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend yield and payout ratio are N/A
- No dividend history or payment
- Company is not profitable and likely cannot sustain dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$0.53
Analyst Target
$5.5
Upside/Downside
+937.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ALUR and closest competitors.
Updated 2026-03-24
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ALUR
Allurion Technologies Inc.
Primary
|
-99.8% | -99.8% | -84.6% | -75.5% | -69.7% | -11.7% |
|
ZCMD
Zhongchao Inc.
Peer
|
-98.6% | -97.8% | -76.2% | -65.0% | +13.5% | -2.1% |
|
EVGN
Evogene Ltd.
Peer
|
-98.3% | -86.8% | -23.5% | -45.0% | +5.7% | -0.8% |
|
BMRA
Biomerica, Inc.
Peer
|
-95.7% | -88.5% | -46.5% | -34.3% | -3.0% | 0.0% |
|
IMRN
Immuron Limited
Peer
|
-85.9% | -59.6% | -51.9% | -61.7% | -3.3% | -1.0% |
ALU
Allurion Technologies Inc.
Primary
5Y
-99.8%
3Y
-99.8%
1Y
-84.6%
6M
-75.5%
1M
-69.7%
1W
-11.7%
ZCM
Zhongchao Inc.
Peer
5Y
-98.6%
3Y
-97.8%
1Y
-76.2%
6M
-65.0%
1M
+13.5%
1W
-2.1%
EVG
Evogene Ltd.
Peer
5Y
-98.3%
3Y
-86.8%
1Y
-23.5%
6M
-45.0%
1M
+5.7%
1W
-0.8%
BMR
Biomerica, Inc.
Peer
5Y
-95.7%
3Y
-88.5%
1Y
-46.5%
6M
-34.3%
1M
-3.0%
1W
0.0%
IMR
Immuron Limited
Peer
5Y
-85.9%
3Y
-59.6%
1Y
-51.9%
6M
-61.7%
1M
-3.3%
1W
-1.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-1.1
PEG Ratio
N/A
P/B Ratio
-0.05
P/S Ratio
0.46
EV/Revenue
4.76
EV/EBITDA
-2.12
Market Cap
$7.92M
Profitability
Profit margins and return metrics
Profit Margin
-187.87%
Operating Margin
-362.3%
Gross Margin
60.99%
ROE
N/A
ROA
-71.87%
Growth
Revenue and earnings growth rates
Revenue Growth
-50.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
1.26
Good
Quick Ratio
0.87
Poor
Cash/Share
$0.66
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Revenue
$0.0B
Gross Margin
49.1%
Op. Margin
-362.3%
Net Margin
-447.1%
Total Assets
$0.0B
Liabilities
$0.1B
Equity
$-0.1B
Debt/Equity
-1.22x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-25
$N/A
2025-11-12
$-1.18
+51.7% surprise
2025-08-19
$-0.87
+1.9% surprise
2025-05-14
$-1.23
+21.7% surprise
Healthcare Sector Comparison
Comparing ALUR against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Profit Margin
-187.87%
This Stock
vs
-16.28%
Sector Avg
+1054.0%
(Superior)
Revenue Growth
-50.5%
This Stock
vs
124.04%
Sector Avg
-140.7%
(Slower)
Current Ratio
1.26
This Stock
vs
4.47
Sector Avg
-71.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ALUR
Allurion Technologies Inc.
|
BEARISH | $7.92M | - | -% | -187.9% | $0.53 | |
|
ZCMD
Zhongchao Inc.
|
BEARISH | $7.92M | - | -24.9% | -55.5% | $2.06 | Compare |
|
EVGN
Evogene Ltd.
|
BEARISH | $7.95M | - | -100.7% | -220.2% | $0.8 | Compare |
|
BMRA
Biomerica, Inc.
|
BEARISH | $7.76M | - | -84.3% | -90.3% | $2.57 | Compare |
|
IMRN
Immuron Limited
|
BEARISH | $8.1M | - | -39.7% | -62.1% | $0.79 | Compare |
ALUR
Allurion...
BEARISH
Mkt Cap
$8M
P/E
-
ROE
-%
Price
$0.53
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-04 | DAVIN MICHAEL R | Director | Sale | 3,212 | $4,918 |
| 2025-11-26 | DAVIN MICHAEL R | Director | Gift | 3,212 | - |
| 2025-11-12 | RTW INVESTMENTS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 1,856,288 | $3,100,001 |
| 2025-11-05 | RTW INVESTMENTS, L.P. | Director and Beneficial Owner of more than 10% of a Class of Security | Option Exercise | 1,492,539 | $5,000,006 |
DAVIN MICHAEL R
Director
2025-12-04
3,212 shares
·
$4,918
DAVIN MICHAEL R
Director
2025-11-26
3,212 shares
RTW INVESTMENTS, L.P.
Beneficial Owner of more than 10% of a Class of Security
2025-11-12
1,856,288 shares
·
$3,100,001
RTW INVESTMENTS, L.P.
Director and Beneficial Owner of more than 10% of a Class of Security
2025-11-05
1,492,539 shares
·
$5,000,006
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
2 analysts
Chardan Capital
2026-02-24
Neutral
Buy
Chardan Capital
2025-11-20
Neutral
Neutral
Past News Coverage
Recent headlines mentioning ALUR from our newsroom.
Newest → oldest
No matching news yet.